In moderate to severe Crohn's disease, a network meta-analysis suggested that TNF inhibitor-based therapy was the most effective option for biologic-naive patients, while upadacitinib (Rinvoq) was most effective for those previously exposed to biologics. ( Gastro Hep Advances )

Real-world data on inflammatory bowel disease showed that lost responses during upadacitinib maintenance can be recaptured by restarting induction dosing. ( Clinical Gastroenterology and Hepatology )

The New England Journal of Medicine published a review on metabolic dysfunction-associated steatotic liver disease (MASLD) , now the most common chronic liver disease worldwide.

Analysis of U.K. Biobank data found a higher risk of irritable bowel syndrome (IBS) in patients with MASLD. ( BMC Gastroenter

See Full Page